Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
Phase IIa study to optimize the dosing regimen and maximize the efficacy of IMCgp100.

Immunocore Limited has announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed.

The company has now initiated a Phase IIa clinical trial in the UK and USA.

Immunocore’s Phase I dose escalation study in 31 patients with late stage malignant melanoma was designed to evaluate the safety of IMCgp100 and to establish a tolerable dose. Dose dependent toxicity has been demonstrated and the MTD established as 600 ng/kg.

Data from the Phase I trial indicate promising early signs of efficacy. Immunocore has now initiated a Phase IIa study to optimize the dosing regimen and maximize the efficacy of IMCgp100.

James Noble, Chief Executive Officer of Immunocore, commented: “We are extremely pleased to have reached the MTD for our lead programme, IMCgp100 in melanoma, which will now enter the next phase of development. This is a very encouraging result for the company, and confirms the potential power of our unique technology platform.”

Earlier this year, Immunocore entered into two major research and licensing agreements with leading pharmaceutical companies Genentech and GlaxoSmithKline for the discovery and development of multiple novel targets using its ImmTAC technology.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immunocore and MedImmune Win the SCRIP Award
Immunocore and MedImmune are working together to generate ImmTACs against selected cancer targets.
Thursday, December 11, 2014
Immunocore and Lilly Enter Immunotherapy Agreement
Agreement to co-discover and co-develop novel cancer therapies.
Thursday, July 17, 2014
Immunocore Announces Re-organization of its Executive Management to Support Business Growth
Re-organization to support the continuing growth of Immunocore and Adaptimmune.
Thursday, March 27, 2014
Immunocore and MedImmune Enter Immunotherapy Agreement
Companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
Wednesday, January 08, 2014
Immunocore Appoints New Chairman of the Board
Dr Jonathan Knowles appointed as Company’s new executive Chairman of the Board of Directors.
Monday, November 18, 2013
Immunocore Appoints Chairman
Immunocore Limited announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect.
Thursday, November 14, 2013
Immunocore Achieves Research Milestone in GSK Collaboration
Under the agreement announced in July, Immunocore will receive up to £142 million in pre-clinical milestone payments across the targets.
Thursday, November 07, 2013
Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma
IMCgp100 for has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed.
Monday, November 04, 2013
Immunocore Named One of Fierce 15 Leading Biotechs of 2013
Immunocore ranked among the top private biotech firms globally.
Thursday, September 26, 2013
Immunocore and Genentech Enter Strategic Alliance
Licensing agreement to develop ImmTACs for multiple cancer targets.
Thursday, June 27, 2013
Revolutionary New Cancer Targeting Technology Described in Nature Medicine
Immunocore scientists manage to overcome cancer problem by boosting the ability of cancer-specific TCRs.
Monday, May 07, 2012
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Fungi – A Promising Source Of Chemical Diversity
Moulds and plants share similar ways in alkaloid biosynthesis .
Great Migration and African-American Genomic Diversity
Study examines genetic data to analyze regional differences in ancestry.
Faster, More Efficient CRISPR Editing
UC Berkeley scientists have developed a quicker and more efficient method to alter the genes of mice with CRISPR-Cas9, simplifying a procedure growing in popularity because of the ease of using the new gene-editing tool.
New Tool Could Change How Infectious Diseases Are Diagnosed
Scientists at the University of Utah School of Medicine, ARUP Laboratories, and IDbyDNA, Inc., have developed ultra-fast, meta-genomics analysis software called Taxonomer that dramatically improves the accuracy and speed of pathogen detection.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!